The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | L | Antineoplastic and immunomodulating agents | |
2 | L01 | Antineoplastic agents | |
3 | L01E | Protein kinase inhibitors | |
4 | L01EK | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors |
Code | Title | |
---|---|---|
L01EK01 | Axitinib | |
L01EK02 | ||
L01EK03 | ||
L01EK04 |
Active Ingredient | Description | |
---|---|---|
Axitinib |
Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival. |
|
Fruquintinib |
Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC50 values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer. |
|
Tivozanib |
Tivozanib potently and selectively blocks all 3 Vascular Endothelial Growth Factor receptors (VEGFR) and has been shown to block various VEGF-induced biochemical and biologic responses in vitro. By blocking VEGF-induced VEGFR activation, tivozanib inhibits angiogenesis and vascular permeability in tumour tissues, leading to inhibition of tumour growth in vivo. |
Title | Information Source | Document Type | |
---|---|---|---|
FOTIVDA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
FRUZAQLA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
INLYTA | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
INLYTA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |